Protein anchoring type copper response photoacoustic probe as well as preparation method and application thereof

By developing a protein-anchored copper-responsive photoacoustic probe with copper ion chelation and protein sulfinic acid cross-linking ability, the specificity of molecular probes in the prior art and long response time in tumor imaging and treatment is solved. The problem has achieved efficient tumor imaging and treatment effects.

CN118930523AActive Publication Date: 2024-11-12SUZHOU UNIV

Patent Information

Application Number
CN202411127205.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-12
Estimated Expiration
2044-08-16

AI Technical Summary

Technical Problem

Existing molecular probes have insufficient specificity in tumor imaging and treatment, long response time, and difficulty in delivery and distribution control, resulting in limited accuracy and effectiveness of detection and treatment.

Method used

A protein-anchored copper-responsive photoacoustic probe has been developed, which has the ability to cross-link copper ion chelate groups and protein sulfonate, which can react specifically in tumor cells, activate photoacoustic properties, and pass copper Ion depletion mechanism inhibits tumor growth.

Benefits of technology

High specific imaging and treatment of tumors are achieved, extending the retention time of the probe in tumor tissue, improving the effectiveness and accuracy of treatment, and significantly inhibiting tumor growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930523A_ABST
    Figure CN118930523A_ABST
Patent Text Reader

Abstract

The invention discloses a protein anchoring type copper response photoacoustic probe and a preparation method and application thereof, the probe can be selectively chelated with copper in tumor cell mitochondria, so that a photoacoustic signal of the probe is activated, and in-situ tracing and quantification of copper ions in a tumor are realized. Meanwhile, copper in mitochondria is exhausted through copper chelation, mitochondrial structure and function damage is caused, and tumor diagnosis and treatment integration is achieved. Besides, the probe can specifically react with protein hyposulphonic acid in mitochondria to form a probe-protein conjugate, so that enrichment of the probe at a tumor site is promoted, an imaging window is prolonged, and the copper depletion treatment effect is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of small molecule photoacoustic probe biological imaging and tumor treatment. Specifically, it relates to a protein-anchored copper-responsive molecular probe and a preparation method thereof, as well as the application of the probe in multimodal imaging and tumor treatment. Background Art

[0002] In the past few decades, the incidence and mortality of cancer have increased significantly, and it has become one of the major threats to human health and life. As one of the core elements of molecular imaging technology, molecular probes play an important role in the precise diagnosis and treatment of cancer. Although a large number of molecular imaging probes have been developed for cancer imaging and treatment, they often fail to achieve the purpose of precise diagnosis and treatment due to poor tumor specificity and the possibility of damaging normal tissues. Based on the characteristics of the tumor microenvironment (TME), scientists have developed a variety of activatable molecular probes that can be triggered by endogenous substances (such as overexpressed enzymes, metals, acidic pH, high-reducing glutathione, and hypoxia) and can specifically destroy cancer cells, thereby reducing the toxic side effects of traditional chemotherapy or radiotherapy on normal tissues. However, these existing probes still have some obvious shortcomings in practical applications. Insufficient specificity is one of the main problems. Many probes may be activated by non-target factors in complex biological environments, resulting in increased background signals and reduced detection accuracy. In addition, long response time is also a key challenge. Some probes have a slow activation process, which limits their effectiveness in applications that require rapid response. The difficulty in controlling delivery and distribution is also an important issue. The distribution of probes in the body may be uneven, affecting the consistency of treatment or detection. Therefore, new technologies need to be developed to effectively solve these problems, thereby significantly improving the application performance of probes. Summary of the invention

[0003] The invention discloses a protein-anchored copper-responsive photoacoustic probe and a preparation method thereof. The probe has a copper ion chelating group and a protein sulfonic acid cross-linking ability group, good biocompatibility, active targeting integrin and near-infrared emission, and can effectively perform photoacoustic imaging and tumor treatment.

[0004] The present invention adopts the following technical solutions: A protein-anchored copper-responsive photoacoustic probe having the following chemical structure:

[0005] The present invention discloses a method for preparing the above-mentioned protein-anchored copper-responsive photoacoustic probe, wherein compound 8 is reacted with compound 5 to obtain the protein-anchored copper-responsive photoacoustic probe. Preferably, the reaction is carried out in the presence of an organic solvent, and the preferred organic solvent includes N,N-dimethylformamide; the reaction time is 0.5 to 10 hours; and the molar ratio of compound 8 to compound 5 is 1: (1 to 5).

[0006] In the present invention, compound 7 reacts with compound 2 to obtain compound 8; preferably, the reaction is carried out in the presence of sodium ascorbate and copper sulfate; the molar ratio of compound 7, compound 2, sodium ascorbate and copper sulfate is 1: (0.8-1.2): (0.05-0.2): (0.05-0.1).

[0007] In the present invention, N-Boc-ethylenediamine reacts with 2-chloromethylpyridine hydrochloride, and then the protecting group is removed by trifluoroacetic acid to obtain compound 5 (DPA); preferably, N-Boc-ethylenediamine and 2-chloromethylpyridine hydrochloride are placed in a small molecule alcohol for reaction to obtain compound 4; compound 4 is deprotected by trifluoroacetic acid in an organic solvent to obtain compound 5.

[0008] The present invention discloses the use of the above-mentioned protein-anchored copper-responsive photoacoustic probe in the preparation of reagents for chelating copper ions and / or cross-linking proteins. The probe has a copper ion chelating group and a protein sulfonic acid cross-linking ability group. Copper is an essential auxiliary factor for enzymes that mediate a series of basic cell functions, including mitochondrial respiration, antioxidant defense, and the biosynthesis of hormones, neurotransmitters and pigments. Disorders in copper storage can induce oxidative stress and cytotoxicity. Therefore, the probe of the present invention can effectively perform photoacoustic imaging and tumor treatment.

[0009] The present invention discloses the use of the above-mentioned protein-anchored copper-responsive photoacoustic probe in imaging or preparing an imaging agent; preferably, the imaging includes fluorescence imaging and / or photoacoustic imaging. Specifically, the present invention discloses the use of the above-mentioned protein-anchored copper-responsive photoacoustic probe in fluorescence imaging and photoacoustic imaging; or in preparing a fluorescence imaging agent and a photoacoustic imaging agent.

[0010] The present invention discloses the use of the protein-anchored copper-responsive photoacoustic probe in the preparation of medicines; preferably, the medicines are diagnostic and / or therapeutic medicines.

[0011] In the above technical solution, the object of administration of the imaging agent or drug includes a tumor.

[0012] The invention discloses an imaging agent or medicine, which comprises the above-mentioned protein-anchored copper-responsive photoacoustic probe and may also comprise other medicine components.

[0013] The invention discloses the application of the protein-anchored copper-responsive photoacoustic probe in increasing the retention time of the probe in tumor tissue or inhibiting tumor, or in preparing a reagent for increasing the retention time of tumor tissue or inhibiting tumor.

[0014] Due to the application of the above technical solution, the present invention has the following advantages compared with the prior art: 1. The present invention designs and synthesizes a new type of anchored molecular probe d-IR-DPA, which can specifically chelate endogenous copper ions in tumors, thereby activating the photoacoustic properties of the probe and achieving copper chelation spatiotemporal tracing; 2. The target probe in the present invention specifically reacts with the protein sulfonic acid in the mitochondria of tumor cells to form a probe-protein conjugate, prolong the probe retention time, and increase the probe enrichment effect. ; 3. The target probe of the present invention chelates with copper ions in tumor cells to cause mitochondrial damage and has a good ability to promote tumor cell apoptosis; 4. The target probe of the present invention undergoes copper chelation in vivo, causing copper depletion, which results in significant inhibition of tumor growth in tumor-bearing mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 Schematic diagram of the synthesis of the protein-anchored copper-responsive photoacoustic probe in Example 1.

[0016] Figure 2 (a) The UV absorption graph of the experimental probe d-IR-DPA in aqueous solution in Example 2, (b) the UV absorption graph of the probe d-IR-DPA and Cu 2+ Changes in UV absorption before and after solution mixing, (c) Probe d-IR-DPA and Cu 2+ Fluorescence emission images of the solutions before and after mixing, (d) probe IR-DPA and Cu 2+ Changes in UV absorption before and after solution mixing, (e) Probe d-IR-RGD and Cu 2+ Changes in UV absorption before and after solution mixing. (f) Probe d-IR-DPA and different concentrations of Cu 2+ Changes in UV absorption of solutions before and after mixing.

[0017] Figure 3 (a) The ultraviolet absorption and IVIS imaging of the supernatant of the experimental probe d-IR-DPA and the control probe IR-PDA after the reaction with BSA in the presence or absence of hydrogen peroxide, (c) the gel electrophoresis experiment of the BSA after the reaction, and the image recording using Coomassie Brilliant Blue staining and IVIS fluorescence imaging. (d) After co-incubation with MDA-MB-231 cells, the confocal imaging of the probe d-IR-DPA and the control probe IR-DPA within 48 hours and (e) the gel electrophoresis after protein extraction.

[0018] Figure 4 (a) Real-time fluorescence images of nude mice bearing subcutaneous MDA-MB-231 tumors after intravenous injection of IR-RGD and d-IR-RGD, (b) quantitative analysis of the fluorescence images in (a), (c) real-time photoacoustic images of nude mice bearing subcutaneous MDA-MB-231 tumors after intravenous injection of IR-DPA and d-IR-DPA, (d) quantitative analysis of the photoacoustic images in (c).

[0019] Figure 5 (a) Photoacoustic images of three different tumor models at different time points after intravenous injection of d-IR-DPA; (b) Photoacoustic images of PA at 680 nm at different time points after injection of d-IR-DPA. 680 / PA 800 Ratio, (c) Quantification of ratio photoacoustic signal in the tumor site 4 hours after injection of d-IR-DPA, (d) After imaging, the mouse tumor was taken and the copper ion content in the tumor was determined by ICP-MS.

[0020] Figure 6 The cytotoxicity changes of the experimental probe d-IR-DPA and the control probe d-IR-RGD and IR-DPA after being co-incubated with MDA-MB-231 cells for 48 h. (a) The copper content in MDA-MB-231 and 3T3 cells was studied by ICP-OES. (b) The cytotoxicity changes of the experimental probe d-IR-DPA and the control probe d-IR-RGD and IR-DPA after being co-incubated with MDA-MB-231 cells for 48 h. (c) The cytotoxicity of the experimental probe d-IR-DPA and the control probe d-IR-RGD and IR-DPA after being co-incubated with 3T3 cells for 48 h. (d) The migration ability of the cells was observed by scratch test after the experimental probe d-IR-DPA and the control probe d-IR-RGD and IR-DPA were incubated with MDA-MB-231 cells for 48 h. (e) The experimental group probe d-IR-DPA and the control group probe d-IR-RGD and IR-DPA were incubated with MDA-MB-231 cells for 48 h, and the live / dead kit was used to observe the changes in cell apoptosis.

[0021] Figure 7To perform JC-1 mitochondrial membrane potential analysis on MDA-MB-231 cells in different treatment groups, (a) subcellular distribution of the probe in MDA-MB-231 cells, (b) JC-1 experiment was used to explore the effect of d-IR-DPA on cell mitochondrial membrane potential, (c) fluorescence ratio in (b), (d) MT-G was used to verify the damage of the probe to mitochondrial structure, red is the probe, green is MT-G, the higher the probe concentration, the more severe the damage, and the weaker the labeling ability of MT-G on mitochondria.

[0022] Figure 8 (a) 19-day continuous change process of tumor inhibition by probe d-IR-DPA in the experimental group and probe d-IR and IR-DPA in the control group, (b) in vitro tumor size on day 19, (c) tumor inhibition curve, (d) relative tumor mass and (e) photos of mice in different groups at different time points during treatment. DETAILED DESCRIPTION

[0023] The protein-anchored copper-responsive photoacoustic probe disclosed in the present invention is a novel integrated diagnosis and treatment protein-anchored copper-responsive photoacoustic probe having the following chemical structure:

[0024] The present invention discloses the application of the protein-anchored copper-responsive photoacoustic probe to the real-time chelation response of endogenous copper in tumors; or the application of the protein-anchored copper-responsive photoacoustic probe in the preparation of fluorescent imaging agents and photoacoustic imaging agents; or the application of the protein-anchored copper-responsive photoacoustic probe in increasing the retention time of the probe in tumor tissues or inhibiting tumors; or the application of the protein-anchored copper-responsive photoacoustic probe in the preparation of reagents for increasing the retention time of the probe in tumor tissues or inhibiting tumors; or the application of the protein-anchored copper-responsive photoacoustic probe in the preparation of reagents for reacting with cytoplasm; or the application of the protein-anchored copper-responsive photoacoustic probe in tumor cells to cross-link with protein sulfonic acid to extend the fluorescence imaging of tumor cells; or the application of the protein-anchored copper-responsive photoacoustic probe in quantitative analysis of copper in tumors by ratiometric photoacoustics; or the application of the protein-anchored copper-responsive photoacoustic probe in tumor cells to chelate with copper ions to inhibit the growth of tumor cells.

[0025] The present invention discloses a method for preparing the above-mentioned protein-anchored copper-responsive photoacoustic probe, wherein compound 8 is reacted with compound 5 to obtain the protein-anchored copper-responsive photoacoustic probe. Preferably, the reaction is carried out in the presence of an organic solvent, and the preferred organic solvent includes N,N-dimethylformamide; the reaction time is 0.5 to 10 hours; and the molar ratio of compound 8 to compound 5 is 1: (1 to 5).

[0026] In the present invention, compound 7 reacts with compound 2 to obtain compound 8; preferably, the reaction is carried out in the presence of sodium ascorbate and copper sulfate; the molar ratio of compound 7, compound 2, sodium ascorbate and copper sulfate is 1: (0.8-1.2): (0.05-0.2): (0.05-0.1).

[0027] In the present invention, N-Boc-ethylenediamine reacts with 2-chloromethylpyridine hydrochloride, and then the protecting group is removed by trifluoroacetic acid to obtain compound 5; preferably, N-Boc-ethylenediamine and 2-chloromethylpyridine hydrochloride are placed in a small molecule alcohol for reaction to obtain compound 4; compound 4 is removed from the protection group by trifluoroacetic acid in an organic solvent to obtain compound 5.

[0028] The method for preparing the above-mentioned protein-anchored copper-responsive photoacoustic probe comprises the following steps: (1) 3,5-dioxocyclohexanecarboxylic acid was activated by NHS and then reacted with 3-azidopropylamine to obtain compound 2; (2) After N-Boc-ethylenediamine reacts with 2-chloromethylpyridine hydrochloride, the protecting group is removed by trifluoroacetic acid to obtain compound 5; (3) Dye IR780 reacts with RGD to obtain compound 7; (4) Compound 7 reacts with compound 2 to obtain compound d-IR; (5) The compound d-IR-RGD reacts with the compound 5 to obtain the integrated diagnosis and treatment protein-anchored copper-responsive photoacoustic probe d-IR-DPA.

[0029] Specifically, the method for preparing the above-mentioned protein-anchored copper-responsive photoacoustic probe comprises the following steps.

[0030] (1) 3,5-dioxetanecarboxylic acid is activated by EDC and NHS in DMF, and then reacted with N,N-diisopropylethylamine (DIPEA) and 3-azidopropylamine for 2-5 hours to obtain compound 2; in the reaction, the reaction of compound 3,5-dioxetanecarboxylic acid with 3-azidopropylamine is carried out in the presence of EDC, NHS and DIPEA; the molar ratio of compound 3,5-dioxetanecarboxylic acid, 3-azidopropylamine, EDC, NHS and DIPEA is 1:1:1.2:1.2:1; the reaction is carried out at room temperature; (2) reacting N-Boc-ethylenediamine and 2-chloromethylpyridine hydrochloride in methanol to obtain compound 4; deprotecting compound 4 in dichloromethane with trifluoroacetic acid to obtain compound 5; in the reaction, the reaction of N-Boc-ethylenediamine and 2-chloromethylpyridine hydrochloride is carried out in methanol; the molar ratio of N-Boc-ethylenediamine to 2-chloromethylpyridine hydrochloride is 1:2.5; deprotecting compound 4 is carried out in a dichloromethane / trifluoroacetic acid mixed solvent; (3) Compound 7 is obtained by reacting compound IR780 with RGD; in the reaction, the molar ratio of cyclic peptide cRGD to dye IR780 is 1:(1-1.2); the reaction is carried out at room temperature; preferably, the reaction is carried out in the presence of sodium ascorbate and copper sulfate; the molar ratio of compound IR780, RGD, sodium ascorbate, and copper sulfate is 1:1:0.1:0.08; preferably, the RGD is azide-functionalized RGD; (4) Compound 7 reacts with compound 2 to obtain compound 8. This is carried out in the presence of sodium ascorbate and copper sulfate; the molar ratio of compound 7, compound 2, sodium ascorbate, and copper sulfate is 1:1:0.1:0.08; (5) Compound 8 and Compound 5 are reacted in N,N-dimethylformamide for 1-5 hours to obtain the integrated diagnosis and treatment protein-anchored copper-responsive photoacoustic probe d-IR-DPA. The molar ratio of Compound 8 to Compound 5 is 1:3.

[0031] The preparation method of the protein-anchored copper-responsive photoacoustic probe and the chemical structural formula of each compound of the present invention are shown in Figure 1 In the compound, the coordinating anion is iodide ion.

[0032] The invention discloses a photoacoustic imaging contrast agent, which is prepared from the protein-anchored copper-responsive photoacoustic probe.

[0033] The invention discloses the application of the protein-anchored copper-responsive photoacoustic probe in increasing the retention time of the probe in tumor tissue or inhibiting tumor, or in preparing an agent for increasing the retention time of the probe in tumor tissue or inhibiting tumor.

[0034] The probe of the present invention is a protein-anchored copper-responsive photoacoustic probe. After entering tumor cells through the targeting peptide, it is enriched in the cell mitochondria and specifically cross-linked with the high-concentration sulfonic acid protein in the mitochondria, and selectively chelates with the copper ions in the mitochondria, thereby activating the photoacoustic properties of the probe and causing the intracellular copper ion depletion effect, resulting in damage to the mitochondrial structure and function, effectively inhibiting tumor growth.

[0035] The steps of synthesizing the integrated diagnosis and treatment protein anchored copper-responsive photoacoustic probe d-IR-DPA of the present invention are as follows: the cyclic peptide N3-RGD reacts with the dye IR780 to obtain the compound IR-RGD; the compound IR-RGD then undergoes a click chemistry reaction with the azide-functionalized 3,5-dioxocyclohexane carboxylic acid to obtain the compound d-IR, and finally, the final probe, i.e., the integrated diagnosis and treatment protein anchored copper-responsive photoacoustic probe d-IR-DPA, is reacted with the compound. IR-DPA and d-IR are used as control group probes.

[0036] The protein-anchored copper-responsive molecular probe d-IR-DPA and the aqueous solutions of the control group probes d-IR and IR-DPA were incubated with tumor cells for 48 hours, and the apoptosis of tumor cells was observed.

[0037] The novel protein-anchored copper-activated photoacoustic probe is used to perform in vivo tumor imaging and inhibition experiments, including the following steps: first, an aqueous solution of the probe d-IR-DPA is injected into the body of a tumor-bearing mouse through the tail vein, and a photoacoustic imaging experiment is performed at different times after the injection, or the probe is injected multiple times to perform a tumor inhibition experiment.

[0038] (1) In vivo photoacoustic imaging: The probe was dissolved in PBS solution (concentration: 100 µM, volume: 200 µL) and injected into nude female mice bearing tumors (MDA-MB-231 human triple-negative breast cancer) by tail vein injection. At the same time, the small animal photoacoustic tomography imaging system was turned on. When the water temperature in the photoacoustic imaging water bath reached 37°C, the anesthetized mice were placed in the water bath and the tumor site images of the mice were scanned. The tumor imaging was monitored at the following 2, 4, 8, 12, 24, and 48 h. Finally, the photoacoustic signal intensity of the mouse tumor site at different time points was calculated using the in vivo imaging analysis software. The obtained photoacoustic imaging data was then reconstructed and analyzed using the MSOT InSight / inVision analysis software.

[0039] (2) Tumor inhibition experiment: MDA-MB-231 cells (5×10 6 ) were implanted into the right back of female nude mice. When the tumor size reached 1000 mm³, the tumor was divided into 100 mm³ and transplanted into the back of nude mice using a puncture needle. After the transplanted tumor was fully fixed and grown, the d-IR-DPA probe (100 µM, 200 µL) or the control probe (100 µM, 200 µL) was injected intravenously. The probe was injected again two days after the first injection, for a total of three treatments. After treatment, the tumor size of each group of mice was subsequently measured and the tumor volume was calculated. After 15 days, the mice were sacrificed and the tumors were further dissected and weighed.

[0040] The present invention will be further described below in conjunction with the accompanying drawings and specific examples. It should be understood that these examples are only used to explain and illustrate the technical solutions in the present invention, and are not intended to limit the scope of the present invention. In addition, unless otherwise specified, the materials, reagents, instruments, etc. used in the following examples can be obtained by commercial means, the specific preparation operations and test methods of the present invention are conventional techniques, and animal experiments comply with the animal experiment regulations of Soochow University.

[0041] Example 1 The preparation method of the protein-anchored copper-responsive photoacoustic probe of the present invention comprises the following steps: Figure 1As shown, in the compound, the coordinating anion is an iodide ion, as shown below.

[0042] Compound 2: Under stirring at 0°C, 20 mg (0.128 mmol) of 3,5-dioxocyclohexanecarboxylic acid, 25 mg (0.13 mmol) of 1-ethyl-3-(3-dimethylaminopropyl) carbonyldiimidazole (EDC) hydrochloride and 15 mg (0.14 mmol) of N-hydroxysuccinimide (NHS) were dissolved in 5 mL of anhydrous DMF, and then stirred at room temperature for 1 hour. Subsequently, 15 mg (0.14 mmol) of 3-azidopropylamine and 10 μL of DIPEA were added to the above solution, and stirring was continued for 4 hours. The solvent was then removed under vacuum, and compound 2 (19 mg, yield 62.3%) was obtained by purification by silica gel chromatography; 1 H NMR (600 MHz, DMSO-d6) δ 5.39 (d, J = 0.7 Hz, 1H), 3.32 (s, 2H), 3.28 (s, 1H), 3.24 (s,2H), 2.72 (dd, J = 17.3, 10.6 Hz, 2H), 2.50 (dd, J = 14.5, 2.8 Hz, 2H), 1.74(s, 2H), 1.71 (d, J = 6.7 Hz, 2H). 13 C NMR (151 MHz, DMSO-d6) δ 181.88,112.95, 58.03, 57.76, 53.39, 45.58, 37.95, 36.67, 31.87, 31.29. MS (MALDI-TOF) Calcd for: C 10 H 14 N4O3([M+H] + ): 239.11, found: 238.99.

[0043] Compound DPA: N-Boc-ethylenediamine (0.4 g, 2.5 mmol), Na2CO3 (1.2 g, 11.3 mmol) and 2-chloromethylpyridine hydrochloride (0.9 g, 5.5 mmol) were dissolved in methanol and refluxed under nitrogen atmosphere for 48 hours. Then, the solvent was removed using a rotary evaporator. The remaining reactants were dissolved in 1N NaOH aqueous solution and extracted with dichloromethane (DCM). After extraction, the organic phase was dried over anhydrous sodium sulfate, and the solvent was evaporated again to obtain a yellow liquid. The crude product was purified by alumina (Al2O3, DCM / MeOH) column chromatography to obtain compound 4. Compound 4 (300 mg, 0.872 mmol) was dissolved in dichloromethane, 3 mL of trifluoroacetic acid (TFA) was added dropwise under ice bath conditions, stirred for 3 hours, and then neutralized with 1N NaOH aqueous solution. The organic phase was dried over anhydrous sodium sulfate, and the solvent was evaporated to obtain a yellow liquid, compound 5 (DPA) (187 mg, yield 89%). MS(MALDI-TOF) Calcd for: C 14 H 18 N4 ([M+H] + ): 243.15, found: 243.37.

[0044] Compound 6: Synthesized and characterized according to existing methods (Journal of the American Chemical Society 2022, 144 (50), 23061-23072). 1 H NMR (600 MHz, DMSO-d6) δ 8.28 (d, J =14.1 Hz, 2H), 7.64 (d, J = 7.4 Hz, 2H), 7.51-7.40 (m, 4H), 7.36-7.25 (m, 2H), 6.37 (d, J = 14.1 Hz, 2H), 4.27 (t, J = 7.3 Hz, 4H), 2.98 (s, 2H), 2.71 (t, J= 5.9 Hz, 4H), 2.50 (d, J = 1.7 Hz, 2H), 2.35 (td, J = 6.8, 2.3 Hz, 4H), 2.00- 1.89 (m, 4H), 1.69 (s, 12H), 1.23 (s, 4H). 13C NMR (151 MHz, DMSO-d6) δ172.43, 148.18, 143.18, 142.01, 141.07, 129.62, 128.61, 126.36, 125.22,122.56, 111.30, 101.53, 83.52, 72.26, 49.06, 42.82, 29.08, 25.94, 20.33,15.30. MS (MALDI-TOF) Calcd for: C 40 H 44 ClN2 ([M] + ): 587.32, found: 587.67.

[0045] Compound 7: Compound 6 (I - Coordination, 13.8 mg, 0. 02 mmol) and N3-RGD (14 mg, 0. 02 mmol) were dissolved in 2 mL of dimethyl sulfoxide as the reaction solution. Then, a copper sulfate pentahydrate aqueous solution (800 μL, 0.05 M) and an aqueous solution of sodium ascorbate of the same volume concentration were mixed, and when the solution turned into an orange-yellow suspension after 5 minutes of ultrasound, it was added dropwise to the reaction solution and stirred at room temperature for 6 hours. After the reaction was completed, it was purified and separated by preparative high performance liquid chromatography to obtain 12.6 mL of compound 7, i.e., probe IR-RGD, with a yield of 46%. 1 H NMR (600 MHz, DMSO- d6) δ 8.42-8.35(m, 1H), 8.23 (dd, J = 19.6, 14.0 Hz, 2H), 8.07 (dd, J = 15.1, 12.4 Hz, 2H),7.93 (s, 1H), 7.84 (s, 1H), 7.62 (s, 4H), 7.43 (d, J = 7.9 Hz, 5H), 7.27 –7.22 (m, 2H), 6.89-6.85 (m, 2H), 6.61-6.58 (m, 2H), 6.35 (d, J = 14.2 Hz,2H), 4.59 (d, J = 6.1 Hz, 1H), 4.30-4.26 (m, 3H), 4.18 (dd, J = 13.9, 6.9 Hz,4H), 4.11 (dd, J = 14.5, 7.8 Hz, 4H), 3.22-3.17 (m, 1H), 3.06-3.00 (m, 2H),2.93 (d, J = 2.6 Hz, 2H), 2.75 (d, J = 7.4 Hz, 2H), 2.69-2.62 (m, 6H), 2.45(ddd, J = 2.9, 1.2, 0.6 Hz, 4H), 2.34 (s, 3H), 2.10-2.05 (m, 2H), 1.87 (s,2H), 1.83 (d, J = 5.4 Hz, 2H), 1.66 (d, J = 2.4 Hz, 15H), 1.55 (s, 1H), 1.41(s, 1H), 1.32-1.28 (m, 2H), 1.20-1.17 (m, 1H), 1.00-0.96 (m, 1H). 13 C NMR (151MHz, DMSO- d6) δ 172.90, 172.14, 172.08, 171.80, 171.25, 170.88, 170.06,169.68, 158.63, 158.42, 156.83, 155.89, 148.28, 145.77, 143.70, 142.88,142.19, 142.10, 141.34, 141.08, 130.13, 129.76, 128.77, 128.72, 127.42,126.59, 126.34, 125.53, 125.16, 122.70, 122.09, 115.05, 111.73, 111.25,102.22, 101.19, 83.68, 72.37, 54.90, 54.45, 51.98, 49.28, 49.14, 49.05,48.99, 43.62, 43.38, 42.82, 42.22, 40.51, 40.40, 36.72, 35.18, 30.71, 29.15,28.95, 29.30, 28.60, 27.64, 27.58, 26.53, 26.00, 25.29, 22.66, 22.22, 20.51,15.43.MS (MALDI-TOF) Calcd for: C 67 H 83 C1N 13 O8 ([M+H] + ): 1233.6, found: 1233.00.

[0046] Compound d-IR-RGD: Compound 7 (15 mg, 0.012 mmol) and compound 2 (2.2 mg, 0.012 mmol) were dissolved in 1 ml of dimethyl sulfoxide. Then, a copper sulfate pentahydrate aqueous solution (800 μL, 0.05 M) and an aqueous solution of sodium ascorbate of the same volume concentration were mixed, and when the solution turned into an orange-yellow suspension after 5 minutes of ultrasound, it was added dropwise to the reaction solution and stirred at room temperature for 6 hours. After the reaction, it was purified and separated by preparative high performance liquid chromatography to obtain 14.1 mg of compound 8, i.e., the control group probe d-IR, with a yield of 78%. According to ESI-MS, its molecular formula is C 63 H 75 N 30 O 2+ , the molecular ion peak is 1173.5688. 1 H NMR (600 MHz, DMSO- d6) δ 8.43 (s, 2H), 8.26 (d, J = 13.9Hz, 2H), 8.12-8.02 (m, 3H), 7.97 (d, J = 7.0 Hz, 1H), 7.92 (s, 1H), 7.87 (s,1H), 7.62 (s, 2H), 7.45-7.38 (m, 3H), 7.30-7.24 (m, 2H), 6.92 (d, J = 8.2 Hz,2H), 6.64 (d, J = 8.2 Hz, 2H), 6.34 (t, J = 14.5 Hz, 2H), 5.31 (d, J = 5.0Hz, 1H), 5.20 (s, 1H), 4.63 (dd, J = 14.6, 8.2 Hz, 1H), 4.31 (d, J = 6.6 Hz,5H), 4.21 (d, J = 6.9 Hz, 1H), 4.15 (dd, J = 14.4, 7.4 Hz, 2H), 4.04 (dd, J =14.9, 7.6 Hz, 2H), 3.96 (s, 2H), 3.66 (s, 1H), 3.33 (dd, J = 10.8, 5.8 Hz,1H), 3.27-3.17 (m, 2H), 3.06 (dd, J = 12.8, 6.3 Hz, 5H), 2.88 (s, 1H), 2.85-2.75 (m, 4H), 2.71-2.61 (m, 5H), 2.44-2.28 (m, 4H), 2.11 (s, 3H), 2.01-1.81(m, 6H), 1.73-1.62 (m, 12H), 1.45 (s, 4H), 1.35 (dd, J = 13.5, 6.3 Hz, 2H),1.28-1.15 (m, 5H), 1.10-0.95 (m, 3H), 0.84 (t, J = 6.9 Hz, 1H). 13 C NMR (151MHz, DMSO- d6) δ 172.51, 172.19, 171.85, 171.34, 170.96, 170.14, 169.75,158.95, 158.70, 158.45, 158.20, 156.88, 155.96, 148.33, 145.85, 143.39,142.22, 141.27, 130.20, 129.81, 128.77, 127.48, 126.48, 125.40, 122.71,122.50, 122.15, 115.12, 111.58, 103.48, 101.88, 65.89, 56.14, 55.20, 54.98,54.54, 52.07, 49.22, 49.08, 48.53, 47.25, 43.57, 36.81, 36.03, 35.25, MS (MALDI-TOF) Calcd for: C 77 H 97 C1N 17 O 11 ([M+H] + ):1473.1, found:1473.3.

[0047] Compound IR-DPA: Compound 7 (15 mg, 0.012 mmol) and compound 5 (8.87 mg, 0.03 mmol) were dissolved in 1 ml of DMF. The mixture was stirred at 50°C for 6 hours. After the reaction, the mixture was purified and separated by preparative HPLC to obtain 9.63 mg of compound 8, i.e., the control group probe IR-DPA, with a yield of 75%. MS (MALDI-TOF) Calcd for: C 81 H 100 N 17 O8 ([M] + ): 1439.79, found: 1439.29.

[0048] Compound d-IR-DPA: Compound d-IR (10 mg, 0.0068 mmol) and compound 5 (6 mg, 0.02 mmol) were dissolved in 1 mL of DMF. The mixture was stirred at 50°C for 6 hours. After the reaction, the mixture was purified and separated by preparative high performance liquid chromatography to obtain 8.32 mg of compound d-IR-DPA with a yield of 73%. 1H NMR (600 MHz, dmso) δ 8.73-8.64 (m, 2H), 8.63-8.56 (m, 1H), 8.39 (s, 1H), 8.08 (d, J = 7.8 Hz, 3H),8.03-7.95 (m, 3H), 7.89 (ddd, J = 31.0, 11.9, 6.4 Hz, 2H), 7.77 (s, 1H), 7.70(d, J = 7.7 Hz, 2H), 7.65-7.57 (m, 2H), 7.52 (d, J = 15.3 Hz, 1H), 7.42 (dd,J = 21.8, 15.7 Hz, 3H), 7.33-7.20 (m, 2H), 7.06 (dd, J = 24.1, 16.2 Hz, 3H),6.92 (d, J = 7.2 Hz, 2H), 6.64 (d, J = 7.2 Hz, 2H), 5.77 (s, 1H), 5.32 (dd, J= 12.3, 7.7 Hz, 1H), 5.19 (s, 1H), 4.65 (dd, J = 20.5, 12.6 Hz, 10H), 4.57(s, 1H), 4.54 (s, 1H), 4.47 (s, 1H), 4.41 (d, J = 12.8 Hz, 1H), 4.36-4.25 (m,3H), 4.24-4.14 (m, 3H), 4.10 (d, J = 18.2 Hz, 3H), 4.03 (d, J = 7.2 Hz, 2H),3.93 (s, 2H), 3.84 (s, 1H), 3.72 (d, J = 19.8 Hz, 1H), 3.65 (s, 1H), 3.55-3.47 (m, 1H), 3.33 (d, J = 5.9 Hz, 1H), 3.29-3.24 (m, 1H), 3.23-3.12 (m, 9H),3.11-3.02 (m, 3H), 2.95 (t, J = 6.0 Hz, 2H), 2.88 (d, J = 1.5 Hz, 3H), 2.83-2.62 (m, 6H), 2.57-2.54 (m, 1H), 2.43 (s, 1H), 2.36 (d, J = 11.3 Hz, 1H),2.08-1.88 (m, 4H), 1.74-1.63 (m, 3H), 1.60-1.42 (m, 6H), 1.35 (d, J = 6.9 Hz, 1H), 1.31-1.19 (m, 6H), 1.04 (s, 1H), 0.84 (t, J = 6.9 Hz, 1H). 13 C NMR (151MHz, DMSO- d6 ) δ 174.83, 172.46, 172.13, 171.54, 171.16, 170.36, 169.97,164.49, 162.75, 162.38, 159.24, 159.02, 158.79, 158.56, 157.24, 156.21,155.58, 152.50, 149.44, 149.08, 148.44, 147.96, 147.72, 146.55, 146.28,143.27, 141.03, 140.17, 139.53, 139.33, 53.71,52.25, 51.75, 49.44, 49.30, 49.02, 47.46, 46.98, 43.69, 37.03, 36.61, 36.21,35.54, 31.71, 31.19, 31.05, 29.61, 29.51, 29.45, 29.40, 29.26, 29.17, 29.12,29.00, 28.89, 28.65, 26.98, 26.14, 25.56, 24.58, 22.98, 22.69, 22.52, 14.35.MS (MALDI-TOF) Calcd for: C 91 H 114 N 21 O 11 ([M] + ): 1676.70.

[0049] Example 2 Physicochemical properties of the probe The experimental probe d-IR-DPA prepared in Example 1 was diluted with ultrapure water to a concentration of 10 μM (completely soluble), and its UV-visible-near-infrared spectrum and fluorescence spectrum were measured using a UV-visible-near-infrared spectrophotometer and a fluorescence spectrophotometer. Figure 2 aThe results show that the maximum absorption of the probe d-IR-DPA is at 620 nm and the maximum emission is at 790 nm. The control group probe IR-DPA, d-IR and the experimental group probe d-IR-DPA were respectively mixed with 10 µM Cu prepared with CuCl2 2+ After 5 minutes of shaking incubation, the maximum UV absorption of the probes d-IR-DPA and IR-DPA both shifted red from 620 nm to 680 nm (e.g. Figure 2 b. Figure 2 c and Figure 2 d), while d-IR-RGD showed no significant change (as shown in Figure 2 e), the effect of different concentrations of copper ions on the probe can be seen in Figure 2 f.

[0050] IR-DPA and d-IR-DPA were diluted with ultrapure water to a concentration of 10 µM, and TCEP-treated bovine serum albumin (BSA) was added, and H2O2 (50 µM) was used as a variable. After mixing, the mixture was shaken at room temperature for 30 minutes, then centrifuged at 12,000 rpm in an ultracentrifuge, and washed three times with PBS buffer. Figure 3 As shown in a and b, through the determination of ultraviolet absorption spectrum and fluorescence spectrum, it was found that under the action of H2O2, the probe d-IR-DPA successfully labeled the BSA pretreated with TCEP, which was manifested by the strong fluorescence signal and ultraviolet peak at 620 nm emitted by the experimental group. The labeling ability of the probe on BSA was further determined by gel electrophoresis experiment, as shown in Figure 3 As shown in c, in the presence of H2O2, the probe d-IR-DPA and BSA co-incubated strips showed strong fluorescence. IR-DPA and d-IR-DPA were added to the culture medium (HyClone DMEM high glucose liquid medium containing 10% FBS) at a concentration of 10 μM and added to MDA-MB-231 cells (2×10 5 After culturing for 8 hours, the probe was washed away and the retention of the probe in the cells was observed continuously for 48 hours. Figure 3 As shown in d, the fluorescence intensity of the probe d-IR-DPA was greater than that of the control group within 48 hours. IR-DPA and d-IR-DPA were added to the culture medium (HyClone DMEM high glucose liquid medium containing 10% FBS) at a concentration of 10 μM and added to MDA-MB-231 cells (2×10 5After culturing for 8 hours, the probe was washed off and the cells were cultured for another 48 hours, during which the culture medium was changed every 6 hours. After the culture was completed, the MDA-MB-231 cell protein was extracted and subjected to electrophoresis gel experiment. After the experiment, the protein was stained with CBB and subjected to two-zone fluorescence imaging. Figure 3 As shown in Figure e, when the amount of proteins in the two groups is roughly the same, the proteins in the cell group incubated with probe d-IR-DPA have obvious fluorescence signals, which confirms that the probe effectively labels the sulfenylated proteins in the cells. The above experiments successfully proved that in the presence of protein sulfenic acid, the probe d-IR-DPA can effectively label sulfenylated proteins to form probe-protein conjugates.

[0051] To investigate the retention of the probe in mouse tumors, IR-RGD and d-IR-RGD were diluted with PBS to a concentration of 100 µM, and 200 µL of IR-RGD or d-IR-RGD was injected into the tail vein. The metabolism of the probe in the tumor at each time point was observed using an IVIS in vivo fluorescence imager. Figure 4 As shown in a, it was found that the fluorescence intensity of the experimental group (d-IR-RGD) at the tumor site was much greater than that of the control group (IR-RGD). Figure 4 b also confirmed this. IR-DPA and d-IR-DPA were diluted with PBS to a concentration of 100 µM, and 200 µL of IR-DPA or d-IR-DPA was injected into the tail vein. The MSOT photoacoustic imaging system was used to observe the metabolism of the probe in the tumor at each time point. Figure 4 As shown in c, it was found that the photoacoustic signal intensity of the experimental group (d-IR-DPA) at the tumor site was much greater than that of the control group (IR-DPA). Figure 4 This was also confirmed by d.

[0052] IR-DPA and d-IR-DPA were diluted with PBS to a concentration of 100 µM 200 µL, respectively. IR-DPA or d-IR-DPA was injected into the tail vein of mice bearing different tumors (MDA-MB-231, MCF-7, HepG2), and photoacoustic images were collected for 4 hours under 680 and 800 nm excitation light using MSOT. After imaging reconstruction, the probe signal in the tumor area was analyzed by ROI using the MSOT imaging system software package. The three tumor masses were removed and digested, and the copper ion content in the tissue was quantitatively analyzed by ICP-MS, and a linear relationship was established with the corresponding ratio photoacoustic signal. In the in vivo imaging study, MDA-MB-231, MCF-7, and HepG2 were selected as tumor models, and 200 µL of the probe d-IR-DPA with a probe concentration of 100 µM was injected into the tail vein, and the photoacoustic signal at 680 nm was observed at different time points. In order to eliminate the interference caused by different probe concentrations, PA800 was used as an internal reference signal. Figure 5 Figure a shows that after the probe was injected, the photoacoustic signal in the tumors of the three tumor model mice increased over time and reached a maximum at 4 hours, and then decreased. Therefore, the maximum time point was selected for ratio photoacoustic quantification. Figure 5 b shows that the ratiometric photoacoustic signal of the MDA-MB-231 subcutaneous tumor model is the strongest, significantly higher than that of the non-TNBC MCF-7 tumor model, indicating that TNBC tumors have a higher copper dependence and copper content, explaining their high metastatic and invasive abilities. Although the photoacoustic signal of HepG2 at 680 nm is similar to that of MDA-MB-231, its signal at 800 nm is stronger, resulting in a ratiometric signal (PA 680 / PA 800 ) decreases, such as Figure 5 c. The copper content in the tumor tissue was further quantified by ICP-MS, as shown in Figure 5 As shown in (d), the results have the same trend as the ratio photoacoustic signal.

[0053] 3T3 cells and MDA-MB-231 cells were digested, centrifuged and lysed, and the intracellular copper ion content was determined using ICP-OES. Figure 6 As shown in a, the copper ion content in MDA-MB-231 cells is greater than that in 3T3 cells. d-IR-RGD, IR-DPA, and d-IR-DPA were added to the culture medium (HyClone DMEM high glucose liquid culture medium containing 10% FBS) at a concentration of 10 µM, and added to MDA-MB-231 cells and 3T3 cells for 48 hours. It was found that compared with normal cells (3T3), they showed a certain toxicity to triple-negative breast cancer (MDA-MB-231), as shown in Fig. Figure 6b and 6c. At the same time, through the cell migration experiment, it can be seen that the experimental group has a better ability to inhibit the proliferation and migration of tumor cells. Figure 6 d. At the same time, the Live-dead reagent showed that the experimental group (d-IR-DPA) showed the ability to induce tumor cell apoptosis. Figure 6 e. (****p<0.0001, by t-test, n=3. ([d-IR-DPA]=[d-IR-RGD]=[IR-DPA]= 10 µM).

[0054] For the mitochondrial damage experiment, d-IR-DPA was added to the culture medium (HyClone DMEM high glucose liquid medium containing 10% FBS) at a concentration of 10 µM and added to MDA-MB-231 cells for 8 h. Mitochondria were then stained with a commercial mitochondrial tracer (Mitotracker-Green), see Figure 7 a, The probe d-IR-DPA was found to be highly targeted to mitochondria. The mitochondrial membrane potential was determined using the indicator JC-1. JC-1 forms J-aggregates and emits red fluorescence in cells with higher mitochondrial membrane potential, while it remains monomeric and emits green fluorescence in cells with lower mitochondrial membrane potential. Representative results of MDA-MB-231 cells treated with d-IR-DPA and control groups are shown in Figure 2. Figure 7 b, where the quantitative red-green fluorescence ratio of the cells is shown in Figure 7 c, MT-G was used to assess the structural integrity of mitochondria after cells were treated with different concentrations of d-IR-DPA. Figure 7 As shown in d, it was found that as the probe concentration increased, the ability of MT-G to stain cell mitochondria decreased, indicating that the mitochondrial structure was damaged.

[0055] Embodiment 3 The MDA-MB-231 cell tumor mass was cut into 80 mm³ and transplanted on the right back of nude mice. After one week of fixation, it grew to 100 mm³. All mice were divided into four groups (n=5). The probe d-IR-DPA (1.5 μg g -1 ) or control probes (PBS, d-IR-RGD, IR-DPA) were injected into nude mice for a total of three treatments, with an interval of two days, see Figure 8 a. After the first probe injection, the tumor size was measured with a vernier caliper for 19 consecutive days, and the tumor changes were photographed with a camera. The results are shown in Figure 1. Figure 8As shown in be, the tumors of mice in the PBS group and d-IR-RGD group grew exponentially, with tumor diameters exceeding 1 cm and accompanied by ulceration. In contrast, the tumors of mice in the IR-DPA group and d-IR-DPA group were generally suppressed, but the tumors in the IR-DPA group recurred later, while the d-IR-DPA group better delayed tumor recurrence, indicating that the probe-modified cyclohexanedione successfully promoted the copper depletion strategy and improved the therapeutic effect. (**p<0.01, ****p<0.0001, by t-test, n=3. ([d-IR-DPA]=[d-IR-RGD]=[IR-DPA]= 1.5 mg / g).

Claims

1. A protein-anchored copper-responsive photoacoustic probe having the following chemical formula: .

2. Use of the protein-anchored copper-responsive photoacoustic probe according to claim 1 in imaging or preparation of imaging agents.

3. The use according to claim 2, characterized in that: The imaging includes fluorescence imaging and / or photoacoustic imaging. Application in fluorescence imaging and photoacoustic imaging; or application of the diagnosis and treatment integrated protein-anchored copper-responsive photoacoustic probe according to claim 1 in the preparation of fluorescence imaging agents and photoacoustic imaging agents.

4. Use of the protein-anchored copper-responsive photoacoustic probe according to claim 1 in the preparation of drugs.

5. The use according to claim 4, characterized in that: The drug is a diagnostic and / or therapeutic drug.

6. Use of the protein-anchored copper-responsive photoacoustic probe according to claim 1 in preparing reagents for chelating copper ions and / or cross-linking proteins.

7. An imaging agent or drug, characterized in that It comprises the protein-anchored copper-responsive photoacoustic probe as described in claim 1.

8. Use of the protein-anchored copper-responsive photoacoustic probe of claim 1 in increasing the retention time of the probe in tumor tissue or inhibiting tumors, or use of the protein-anchored copper-responsive photoacoustic probe of claim 1 in preparing an agent for increasing the retention time of the probe in tumor tissue or inhibiting tumors.

9. The method for preparing the protein-anchored copper-responsive photoacoustic probe according to claim 1, characterized in that: Compound 8 reacts with compound 5 to obtain the protein-anchored copper-responsive photoacoustic probe; The chemical structure of compound 5 is as follows: ; The chemical structure of compound 8 is as follows: 。 10. Use of compound 8 and compound 5 in the preparation of the protein-anchored copper-responsive photoacoustic probe according to claim 1.

Citation Information

Patent Citations

  • Amino cyanine fluorescent dyes and preparation method therefor and application thereof

    CN105111773A

  • Multi-modal probe as well as preparation method and application thereof

    CN112521373A

  • Diagnosis and treatment integrated nucleic acid anchoring type fluorescent probe as well as preparation method and application thereof

    CN115998908A

Cited By

  • Molecular probe for detecting living copper ions as well as preparation method and application of molecular probe

    CN119874721A

  • Tumor-targeted covalent binding type radionuclide probe as well as preparation method and application thereof

    CN119925646A

  • Novel copper chelating nano-drug and preparation method thereof

    CN121401449A

  • Ratio-dependent probe compound, preparation method thereof, Cu (I) response photoacoustic probe composition and application

    CN121824584A